Anzeige
Mehr »
Dienstag, 02.06.2026 - Börsentäglich über 12.000 News
Entsteht hier die nächste Quantum-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14156 | ISIN: GB00BYMT0J19 | Ticker-Symbol: LIA
Tradegate
01.06.26 | 09:30
63,50 Euro
0,00 % 0,00
1-Jahres-Chart
LIVANOVA PLC Chart 1 Jahr
5-Tage-Chart
LIVANOVA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
62,5063,0022:06
63,5064,0016:48

Aktuelle News zur LIVANOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.LivaNova names new head of CardioPulmonary unit-
21.05.LivaNova names Stefano Folli as cardiopulmonary president3
21.05.Führungswechsel bei LivaNova: Stefano Folli übernimmt Leitung des Geschäftsbereichs Kardiotechnik6
21.05.LivaNova PLC: LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit313LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding...
► Artikel lesen
19.05.LivaNova PLC: LivaNova to Present at Goldman Sachs Global Healthcare Conference in June248LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir...
► Artikel lesen
06.05.LivaNova forecasts 7%-8% 2026 revenue growth while outlining $4.20-$4.30 EPS3
06.05.LivaNova PLC - 10-Q, Quarterly Report2
LIVANOVA Aktie jetzt für 0€ handeln
06.05.LivaNova übertrifft Q1-Prognosen 2026: Aktie legt deutlich zu3
06.05.LivaNova Q1 2026 Earnings Call Transcript1
06.05.LivaNova übertrifft Erwartungen, doch verhaltener Ausblick belastet die Aktie1
06.05.LivaNova PLC Non-GAAP EPS of $0.98 beats by $0.08, revenue of $362.3M beats by $16.19M3
06.05.LivaNova PLC: LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance559Delivered double-digit reported and constant-currency revenue growth Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) Received U.S. Food and Drug Administration...
► Artikel lesen
06.05.LivaNova PLC - 8-K, Current Report2
21.04.LivaNova reports positive findings for sleep apnea neuromod1
20.04.LivaNova PLC: Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea409Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time First rigorous RCT study design in HGNS space supports...
► Artikel lesen
25.03.LivaNova PLC: LivaNova to Announce First-Quarter 2026 Results313LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m....
► Artikel lesen
19.03.LivaNova gains FDA premarket approval for aura6000 for sleep apnea2
19.03.LivaNova wins FDA premarket approval for neuromod for sleep apnea1
19.03.LivaNova wins FDA approval for sleep apnea nerve device3
19.03.LivaNova PLC: LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea396First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language Next-generation, MRI-compatible device expected...
► Artikel lesen
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1